8-K current report · filed Sep 15, 2026

Parabilis Medicines Inc (PBLS) 8-K Current Report: September 15, 2026

Item 7.01PBLS overview

Short answer

Parabilis Medicines Inc (PBLS) filed an 8-K current report with the SEC on September 15, 2026 reporting Item 7.01 (Regulation FD Disclosure). Updated Phase 1/2 zolucatetide data planned for oral presentation at ESMO Congress 2026.

Parabilis Medicines Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Updated Phase 1/2 zolucatetide data planned for oral presentation at ESMO Congress 2026
  • Data concern patients with desmoid tumors, a key clinical development milestone
  • Presentation scheduled October 24 at 2:45pm CEST in Madrid during a sarcoma-focused session
  • Investors may assess efficacy and safety results for implications on zolucatetide’s development path

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Parabilis Medicines Inc 8-K filings

Get the next PBLS 8-K as it lands

Follow PBLS for push alerts, or ask the research agent what this filing means.